LEADER 04175nam  22008535  450 
001 9910300206203321
005 20230810184032.0
010   $a3-319-11719-X
024 7 $a10.1007/978-3-319-11719-5
035   $a(CKB)3710000000342451
035   $a(EBL)1966854
035   $a(SSID)ssj0001424502
035   $a(PQKBManifestationID)11789939
035   $a(PQKBTitleCode)TC0001424502
035   $a(PQKBWorkID)11368542
035   $a(PQKB)10650630
035   $a(DE-He213)978-3-319-11719-5
035   $a(MiAaPQ)EBC1966854
035   $a(PPN)183518918
035   $a(EXLCZ)993710000000342451
100   $a20150116d2015      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aIndividualized Medicine $eEthical, Economical and Historical Perspectives /$fedited by Tobias Fischer, Martin Langanke, Paul Marschall, Susanne Michl
205   $a1st ed. 2015.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015.
215   $a1 online resource (326 p.)
225 1 $aAdvances in Predictive, Preventive and Personalised Medicine,$x2211-3509 ;$v7
300   $aIncludes index.
311   $a3-319-11718-1 
327   $aPreface -- Introduction -- Definition and concept of Individualized Medicine -- Perspectives of socio-cultural and historical studies -- Medical perspectives -- Concept-based ethical questions -- Applied research ethics -- Health economic assessment of Individualized Medicine -- Conclusions and recommendations -- Index.
330   $aIn 2009 the University Medicine Greifswald launched the ?Greifswald Approach to Individualized Medicine? (GANI_MED) to implement biomarker-based individualized diagnostic and therapeutic strategies in clinical settings. Individualized Medicine (IM) has led not only to controversies about its potentials, but also about its societal, ethical and health economic implications. This anthology focusses on these areas and includes ? next to clinical examples illustrating how the integrated analysis of biomarkers leads to significant improvement of therapeutic outcomes for a subgroup of patients ? chapters about the definition, history and epistemology of IM. Additionally there is a focus on conceptual philosophical questions as well as challenges for applied research ethics (informed consent process, the IT-based consent management and the handling of incidental findings). Finally it pays attention to health economic aspects.  The possibilities of IM to initiate a paradigm shift in the German health care provision are investigated. Furthermore, it is asked whether the G-DRG system is ready for the implementation of such approaches into clinical routine.
410  0$aAdvances in Predictive, Preventive and Personalised Medicine,$x2211-3509 ;$v7
606   $aMedicine$xResearch
606   $aBiology$xResearch
606   $aBioethics
606   $aEthics
606   $aBusiness
606   $aManagement science
606   $aHistory
606   $aBiomedical Research
606   $aBioethics
606   $aMoral Philosophy and Applied Ethics
606   $aBusiness and Management
606   $aHistory
615  0$aMedicine$xResearch.
615  0$aBiology$xResearch.
615  0$aBioethics.
615  0$aEthics.
615  0$aBusiness.
615  0$aManagement science.
615  0$aHistory.
615 14$aBiomedical Research.
615 24$aBioethics.
615 24$aMoral Philosophy and Applied Ethics.
615 24$aBusiness and Management.
615 24$aHistory.
676   $a170
676   $a174.2
676   $a330
676   $a610
676   $a610.1
676   $a900
702   $aFischer$b Tobias$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aLanganke$b Martin$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aMarschall$b Paul$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aMichl$b Susanne$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910300206203321
996   $aIndividualized Medicine$91866568
997   $aUNINA